Washington: A low-cost coronavirus vaccine in the United States (US) is in the experimental phase that will have the potential to withstand most variants of the virus and protect the human body.

Experts at the University of Virginia in the United States are working on a universal code vaccine that targets the spike protein of the virus that is common to all types of coronaviruses. However, a single dose of this universal covid vaccine can cost less than a dollar.
The medical journal Proceedings of the National Academy of Sciences has released the results of a trial of this vaccine on animals.
The results showed that the vaccine protected animals from diseases caused by two types of coronaviruses, one of which was the measles-causing virus and the other the cholera-causing virus.
The researchers said that the two coronaviruses are somewhat similar, suggesting that the vaccine could protect against several different types of COVID-19.
Medical experts say that a universal vaccine could be the best way to prevent the common coronavirus, other than the new coronavirus, which causes 25% of the world's flu cases.
The cost of the new vaccine can be very low because it is based on a genetically modified bacterium that will cost a lot less to develop than existing cod vaccines.
According to the magazine, the current cost of MRNA COVID vaccines is $10 per dose, making them difficult to use in developing countries, while a single dose of vaccines made to prevent various bacterial diseases costs less than a dollar.
The vaccine, NDV-HXP-S, can be stored at 2-8 degrees Celsius and is made in eggs, a method also used for flu vaccine manufacturing. These factors mean that affordable manufacturing capacity already exists in each of the countries involved with trials.
The vaccine uses a highly stabilized spike protein from the surface of the coronavirus to train the human immune system to recognize and fight infection. This modified spike protein, dubbed HexaPro and engineered by three faculty labs at UT Austin was found in earlier research to be promising for use in robust vaccines.

What we know about the shooting at the White House Correspondents’ Dinner
- 2 hours ago
Iran threatens painful response if US resumes attacks, oil prices seesaw
- 12 hours ago

The Verge’s 2026 Mother’s Day gift guide
- 4 hours ago
International Jazz Day observed
- 13 hours ago

This is what it takes to become Trump’s attorney general
- 2 hours ago
PM Shehbaz approves one-month extension in subsidy for transport
- 13 hours ago

Amazon snaps up Oprah Winfrey’s podcast
- 4 hours ago

Trump fires the entire National Science Board
- 4 hours ago
Live Nation lost. Will anything change for ticket prices?
- 2 hours ago

The Govee smart lamp brightened up my room, and then my life
- 4 hours ago

The plan to quietly kill Coyote v. Acme blew up in David Zaslav’s face
- 4 hours ago

Is this Samsung’s upcoming wide foldable?
- 4 hours ago



.jpeg&w=3840&q=75)

